We are live on ! Find out more
SMMT icon

Summit Therapeutics
SMMT

91 hedge funds and large institutions have $37.1M invested in Summit Therapeutics in 2023 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 34 increasing their positions, 11 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

429% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 7

209% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 11

49% more funds holding

Funds holding: 61 → 91 (+30)

36% more call options, than puts

Call options by funds: $2.22M | Put options by funds: $1.64M

7% more capital invested

Capital invested by funds: $34.6M → $37.1M (+$2.51M)

1% less ownership

Funds ownership: 4.03% → 3.02% (-1%)

Holders
91
Holders Change
+30
Holders Change %
+49.18%
% of All Funds
1.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
37
Increased
34
Reduced
11
Closed
7
Calls
$2.22M
Puts
$1.64M
Net Calls
+$585K
Net Calls Change
-$367K

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$11.7M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$3.84M
3
BlackRock
BlackRock
New York
+$3.57M
4
Millennium Management
Millennium Management
New York
+$2.47M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.68M

Top Sellers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
-$1.12M
2
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale
Germany
-$531K
3
BCM
Bridgeway Capital Management
Texas
-$379K
4
KI
Kapitalo Investimentos
Brazil
-$243K
5
6CM
683 Capital Management
New York
-$216K
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$11M +$11.7M +4,304,705 +215%
BlackRock
2
BlackRock
New York
$3.23M +$3.57M +1,310,393 +245%
Susquehanna International Group
3
Susquehanna International Group
Pennsylvania
$2.95M +$3.84M +1,408,141 +502%
Vanguard Group
4
Vanguard Group
Pennsylvania
$2.56M +$58.8K +21,571 +1%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$1.91M +$1.68M +617,308 +131%
Millennium Management
6
Millennium Management
New York
$1.58M +$2.47M +903,933 New
AIC
7
AWM Investment Company
New York
$1.4M +$1.36M +500,001 +167%
Morgan Stanley
8
Morgan Stanley
New York
$1.35M +$1.5M +550,834 +252%
SPIA
9
Steward Partners Investment Advisory
New York
$1.1M +$888K +325,570 +107%
CL
10
CSS LLC
Illinois
$915K +$1.43M +522,610 New
Two Sigma Investments
11
Two Sigma Investments
New York
$903K +$627K +229,738 +80%
Goldman Sachs
12
Goldman Sachs
New York
$772K +$1.05M +385,378 +694%
Jane Street
13
Jane Street
New York
$726K +$978K +358,436 +633%
HF
14
HRT Financial
New York
$696K +$980K +359,477 +936%
Squarepoint
15
Squarepoint
New York
$500K +$779K +285,578 New
Barclays
16
Barclays
United Kingdom
$431K +$634K +232,605 +1,678%
Marshall Wace
17
Marshall Wace
United Kingdom
$375K -$1.12M -408,833 -66%
UBS Group
18
UBS Group
Switzerland
$284K +$436K +160,009 +6,590%
BFM
19
Boothbay Fund Management
New York
$275K -$175K -64,210 -29%
Osaic Holdings
20
Osaic Holdings
Arizona
$272K +$298K +109,395 +237%
AGM
21
Alpine Global Management
New York
$254K -$158K -57,928 -29%
Group One Trading
22
Group One Trading
Illinois
$246K +$375K +137,666 +4,593%
SFI
23
Susquehanna Fundamental Investments
Pennsylvania
$221K +$235K +86,212 +215%
State Street
24
State Street
Massachusetts
$214K +$93.8K +34,400 +39%
Verition Fund Management
25
Verition Fund Management
Connecticut
$203K +$316K +116,022 New
1
2 3 4

SMMT Hedge Fund Activity: Q1 2023 in Review

91 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q1 2023, worth a combined $37.1M — up 7.3% from $34.6M a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new SMMT positions and 7 closed out — a net gain of 30 holders — while 34 added to existing stakes and 11 trimmed.

The largest buyer was Baker Bros. Advisors, adding an estimated $11.7M. The largest seller was Marshall Wace, cutting an estimated $1.12M.

  • 91 institutional investors held Summit Therapeutics (SMMT) as of Q1 2023, up from 61 in Q4 2022.
  • Funds reported $37.1M of Summit Therapeutics stock for Q1 2023, up 7.3% quarter-over-quarter.
  • 37 funds opened new Summit Therapeutics positions in Q1 2023 and 7 closed out, a net change of +30 holders.
  • The largest Summit Therapeutics buyer in Q1 2023 was Baker Bros. Advisors, an estimated $11.7M added.
  • The largest Summit Therapeutics seller in Q1 2023 was Marshall Wace, an estimated $1.12M sold.

Based on aggregated 13F filings for Q1 2023.